We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Mark is an entrepreneurial scientist and an experienced biotech business executive. He is an expert in Molecular Biology and Genetics applied to complex organisms and is the founding CEO of a new gene editing company, LifeEDIT, a spinoff of AgBiome. Mark began his career at Genentech where he was involved in the early discovery projects for Herceptin and Avastin. He was a Founder and CSO of Deltagen, an early stage discovery company in mammalian genomics, which went public in 2000 with over 200 employees. He served recently as Executive Director of the IMPC and Senior Consultant to the National Human Genome Research Institute.
Mark was also Co-Founder and CEO of Glialogix, a company that developed a pharmaceutical agent to a novel target involved in Neurodegeneration.
Mark received his Ph.D. in Biology at Brandeis University and an A.B. from Princeton in Biochemical Sciences.
This speaker's sessions: